Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Solvayin
the ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark Solvay' s performance against key rivals in the ethical
pharmaceutical sector
- Assess the impact of Solvay' s acquisition of Fournier, including the
significant expansion of its CV sales force
- Analyze how the delayed launch of antipsychotic bifeprunox will impact
Solvay' s commercial performance over 2006-12
View Cart
